MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma
Status:
Terminated
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2a, open-label, parallel group, partly randomized dose escalation trial to
assess the safety and efficacy of a low dose, an intermediate dose, and high dose MSB0010445
given by intravenous infusion to subjects with advanced (unresectable or metastatic) melanoma
in combination with stereotactic body radiation therapy (SBRT).